Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)

• Prif Awduron: Si Su (Awdur), Liuqing Wu (Awdur), Guibao Zhou (Awdur), Lingling Peng (Awdur), Huanzhe Zhao (Awdur), Xiao Wang (Awdur), Kuan Li (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2023-11-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Objective: To investigate adverse events (AEs) associated with denosumab (Dmab) and zoledronic acid (ZA), compare their association strengths, and explore potential applications to provide clinical reference.Methods: We collected data from FAERS from January 2004 to November 2022 and mined AE signal...